<DOC>
	<DOCNO>NCT02288975</DOCNO>
	<brief_summary>The aim study investigate effect CytoSorb® treatment within first 48 hour septic shock organ dysfunction , microcirculation cytokine storm monitor leukocyte activation inflammatory mediator .</brief_summary>
	<brief_title>Adsorbtion Cytokines Early Septic Shock : ACESS Study</brief_title>
	<detailed_description />
	<mesh_term>Shock</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
	<criteria>Signs hypoperfusion : serum lactate &gt; 2 mmol/L , low central venous oxygen saturation ( ScvO2 ) ( &lt; 70 % ) high ScvO2 ( &gt; 85 % ) , metabolic acidosis , oligoanuria , high venoustoarterial CO2gap ( dCO2 &gt; 6 mm Hg ) Hemodynamic support vasopressor Procalcitonin level ≥ 3 ng/ml Invasive hemodynamic monitoring Written inform content Patients 18 year Pregnancy ( bHCG test positivity ) Surgical intervention context septic insult New York Heart Association IV heart failure Acute coronary syndrome Need acute chronic hemodialysis Acute haematological malignancy Cardiogenic shock Post cardiopulmonary resuscitation care Immunosuppression , systemic steroid therapy ( &gt; 10mg prednisolon/day ) Human immunodeficiency virus infection ( HIV ) active AIDS Patients donate organ Thrombocytopenia ( &lt; 20.000/ml ) More 10 % body surface area third degree burn</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hemoadsorption</keyword>
	<keyword>extracorporeal blood purification</keyword>
	<keyword>CytoSorb</keyword>
	<keyword>hemofiltration</keyword>
	<keyword>SIRS</keyword>
	<keyword>sepsis</keyword>
	<keyword>septic shock</keyword>
	<keyword>membrane</keyword>
	<keyword>ICU</keyword>
	<keyword>dialysis</keyword>
	<keyword>adsorption</keyword>
</DOC>